SOX18 knockdown suppresses the proliferation and metastasis, and induces the apoptosis of osteosarcoma cells

Wu,Zhong; Liu,Junjian; Wang,Jianguang; Zhang,Fan

doi:10.3892/mmr.2015.4541

SOX18 knockdown suppresses the proliferation and metastasis, and induces the apoptosis of osteosarcoma cells

Authors:
- Zhong Wu
- Junjian Liu
- Jianguang Wang
- Fan Zhang
View Affiliations

Affiliations: Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
Published online on: November 10, 2015 https://doi.org/10.3892/mmr.2015.4541
Pages: 497-504

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sex determining region Y‑box 18 (SOX18) has been found to be overexpressed in several types of tumor. However, the molecular mechanism underlying the biological function of SOX18 in osteosarcoma remains to be elucidated. The present study aimed to elucidate the roles of SOX18 in regulating the biological behavior of osteosarcoma cells. First, SOX18 mRNA expression was analyzed in osteosarcoma tissues using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The results demonstrated that the expression of SOX18 was elevated in osteosarcoma tissue, compared with normal bone tissue. In addition, the knockdown of SOX18 in U2OS or MG63 osteosarcoma cells inhibited cell proliferation and significantly increased the population of cells in the S‑phase of the cell cycle, as measured by the CCK‑8 assay and flow cytometric analysis, respectively. Additionally, suppression of the expression of SOX18 in the osteosarcoma cells significantly induced cell apoptosis as evaluated by annexin V/propidium iodide staining and flow cytometric analysis. The downregulation of SOX18 was found to significantly inhibit cell adhesion and invasion. The mRNA and protein expression levels of transforming growth factor‑β, platelet‑derived growth factor (PDGF)‑A, PDGF‑B and RhoA were also reduced by SOX18 silencing, as assessed by RT‑qPCR and western blot analysis, respectively. These results indicated that SOX18 may function as an oncogene, and may provide a novel and promising therapeutic strategy for osteosarcoma.

View Figures

View References

1	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
2	Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT and Miser JS: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the children's cancer group. J Clin Oncol. 15:76–84. 1997.PubMed/NCBI
3	Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M and Campanacci M: Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: An updated report. J Clin Oncol. 18:4016–4027. 2000.PubMed/NCBI
4	Rytting M, Pearson P, Raymond AK, Ayala A, Murray J, Yasko AW, Johnson M and Jaffe N: Osteosarcoma in preadolescent patients. Clin Orthop Relat Res. 39–50. 2000. View Article : Google Scholar : PubMed/NCBI
5	Ferguson WS and Goorin AM: Current treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001. View Article : Google Scholar : PubMed/NCBI
6	Hosking BM, Muscat GE, Koopman PA, Dowhan DH and Dunn TL: Trans-activation and DNA-binding properties of the transcription factor, Sox-18. Nucleic Acids Res. 23:2626–2628. 1995. View Article : Google Scholar : PubMed/NCBI
7	Hosking BM, Wyeth JR, Pennisi DJ, Wang SC, Koopman P and Muscat GE: Cloning and functional analysis of the Sry-related HMG box gene, Sox18. Gene. 262:239–247. 2001. View Article : Google Scholar : PubMed/NCBI
8	Darby IA, Bisucci T, Raghoenath S, Olsson J, Muscat GE and Koopman P: Sox18 is transiently expressed during angiogenesis in granulation tissue of skin wounds with an identical expression pattern to Flk-1 mRNA. Lab Invest. 81:937–943. 2001. View Article : Google Scholar : PubMed/NCBI
9	Young N, Hahn CN, Poh A, Dong C, Wilhelm D, Olsson J, Muscat GE, Parsons P, Gamble JR and Koopman P: Effect of disrupted SOX18 transcription factor function on tumor growth, vascularization and endothelial development. J Natl Cancer Inst. 98:1060–1067. 2006. View Article : Google Scholar : PubMed/NCBI
10	Eom BW, Jo MJ, Kook MC, Ryu KW, Choi IJ, Nam BH, Kim YW and Lee JH: The lymphangiogenic factor SOX 18: A key indicator to stage gastric tumor progression. Int J Cancer. 131:41–48. 2012. View Article : Google Scholar
11	Jethon A, P ula B, Olbromsk i M, Wer ynska B, Muszczynska-Bernhard B, Witkiewicz W, Dziegiel P and Podhorska-Okolow M: Prognostic significance of SOX18 expression in non-small cell lung cancer. Int J Oncol. 46:123–132. 2015.
12	Pula B, Kobierzycki C, Solinski D, Olbromski M, Nowak-Markwitz E, Spaczynski M, Kedzia W, Zabel M and Dziegiel P: SOX18 expression predicts response to platinum-based chemotherapy in ovarian cancer. Anticancer Res. 34:4029–4037. 2014.PubMed/NCBI
13	Pula B, Olbromski M, Wojnar A, Gomulkiewicz A, Witkiewicz W, Ugorski M, Dziegiel P and Podhorska-Okolow M: Impact of SOX18 expression in cancer cells and vessels on the outcome of invasive ductal breast carcinoma. Cell Oncol (Dordr). 36:469–483. 2013. View Article : Google Scholar
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
15	Henry MK, Lynch JT, Eapen AK and Quelle FW: DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. Blood. 98:834–841. 2001. View Article : Google Scholar : PubMed/NCBI
16	Silletti S, Paku S and Raz A: Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization. Int J Cancer. 76:120–128. 1998. View Article : Google Scholar : PubMed/NCBI
17	Mareel M, Oliveira MJ and Madani I: Cancer invasion and metastasis: Interacting ecosystems. Virchows Arch. 454:599–622. 2009. View Article : Google Scholar : PubMed/NCBI
18	Wakefield LM and Roberts AB: TGF-beta signaling: Positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 12:22–29. 2002. View Article : Google Scholar : PubMed/NCBI
19	Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, Tanaka M, Shinagawa K, Tanaka S, Yasui W and Chayama K: Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci. 101:1984–1989. 2010. View Article : Google Scholar : PubMed/NCBI
20	Donnem T, Al-Saad S, Al-Shibli K, Busund LT and Bremnes RM: Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol. 21:223–231. 2010. View Article : Google Scholar
21	Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H and Grünert S: Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest. 116:1561–1570. 2006. View Article : Google Scholar : PubMed/NCBI
22	Struckhoff AP, Rana MK and Worthylake RA: RhoA can lead the way in tumor cell invasion and metastasis. Front Biosci (Landmark Ed). 16:1915–1926. 2011. View Article : Google Scholar
23	Yan G, Zou R, Chen Z, Fan B, Wang Z, Wang Y, Yin X, Zhang D, Tong L, Yang F, et al: Silencing RhoA inhibits migration and invasion through Wnt/β-catenin pathway and growth through cell cycle regulation in human tongue cancer. Acta Biochim Biophys Sin (Shanghai). 46:682–690. 2014. View Article : Google Scholar
24	Yoshioka K, Nakamori S and Itoh K: Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res. 59:2004–2010. 1999.PubMed/NCBI
25	Garcia-Ramírez M, Martinez-González J, Juan-Babot JO, Rodríguez C and Badimon L: Transcription factor SOX18 is expressed in human coronary atherosclerotic lesions and regulates DNA synthesis and vascular cell growth. Arterioscler Thromb Vasc Biol. 25:2398–2403. 2005. View Article : Google Scholar : PubMed/NCBI
26	Duong T, Proulx ST, Luciani P, Leroux JC, Detmar M, Koopman P and Francois M: Genetic ablation of SOX18 function suppresses tumor lymphangiogenesis and metastasis of melanoma in mice. Cancer Res. 72:3105–3114. 2012. View Article : Google Scholar : PubMed/NCBI
27	Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 15:275–286. 2004. View Article : Google Scholar : PubMed/NCBI
28	Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P and Fidler IJ: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 95:458–470. 2003. View Article : Google Scholar : PubMed/NCBI
29	Sulzbacher I, Birner P, Trieb K, Träxler M, Lang S and Chott A: Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol. 16:66–71. 2003. View Article : Google Scholar : PubMed/NCBI
30	Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, D'Amato RJ, Klement GL and Folkman J: VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 15:265–273. 2012. View Article : Google Scholar : PubMed/NCBI
31	Ariad S, Seymour L and Bezwoda WR: Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression. Breast cancer Res Treat. 20:11–17. 1991. View Article : Google Scholar : PubMed/NCBI
32	Abraham MT, Kuriakose MA, Sacks PG, Yee H, Chiriboga L, Bearer EL and Delacure MD: Motility-related proteins as markers for head and neck squamous cell cancer. Laryngoscope. 111:1285–1289. 2001. View Article : Google Scholar : PubMed/NCBI
33	Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest. 83:861–870. 2003. View Article : Google Scholar : PubMed/NCBI
34	Kamai T, Arai K, Tsujii T, Honda M and Yoshida K: Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU International. 87:227–231. 2001. View Article : Google Scholar : PubMed/NCBI
35	Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 9:2632–2641. 2003.PubMed/NCBI
36	Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y and Fan D: Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res. 10:6239–6247. 2004. View Article : Google Scholar : PubMed/NCBI
37	Pillé JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, et al: Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther. 11:267–274. 2005. View Article : Google Scholar : PubMed/NCBI